Subcutaneous Immunoglobulin NextGen 16%

immunoglobulin G (IgG) subcutaneous formulation · CSL Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Subcutaneous Immunoglobulin NextGen 16%, covering 2012-06-07 to 2012-06-07. Get the full timeline:

Most recent: Clinical Trial Update: Subcutaneous Ig NextGen 16% in PID Patients [Phase 3]